Skip to main content
. 2020 Sep 15;7:546. doi: 10.3389/fmed.2020.00546

Figure 7.

Figure 7

Azithromycin activity in maintaining the integrity of tight junctions. (A) Alveoli, (B) Tight junction, (C) Lung infection by SARS-CoV-2, (D) Tight junction disruption caused by virus interleukin 6, tumor necrosis factor and interferon α, (E) SARS-CoV-2 entrance, (F) Administration of azithromycin, and (G) Restoration of tight junctions.